ଫିନାଷ୍ଟେରାଇଡ

ଉଇକିପିଡ଼ିଆ‌ରୁ
ଫିନାଷ୍ଟେରାଇଡ
Clinical data
Trade namesProscar, Propecia, others
SynonymsMK-906; YM-152; L-652,931; 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androst-1-en-3-one; N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
AHFS/Drugs.commonograph
MedlinePlusa698016
data
Pregnancy
category
  • X (will cause birth defects)
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Bioavailability65%[୧]
Protein binding90%[୧]
MetabolismLiver (CYP3A4, ALDH)[୧]
Elimination half-lifeAdults: 5–6 hours[୧]
Elderly: >8 hours[୧]
ExcretionFeces: 57%[୧]
Urine: 40%[୧]
Identifiers
  • (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
ECHA InfoCard100.149.445 Edit this at Wikidata
Chemical and physical data
FormulaC23H36N2O2
Molar mass୩୭୨.୫୫ g·mol−1
3D model (JSmol)
  • O=C(NC(C)(C)C)[C@@H]2[C@]1(CC[C@H]3[C@H]([C@@H]1CC2)CC[C@H]4NC(=O)\C=C/[C@]34C)C
  • InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 checkY
  • Key:DBEPLOCGEIEOCV-WSBQPABSSA-N checkY
  (verify)

ଫିନାଷ୍ଟେରାଇଡ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବିକ୍ରୟ ନାମ ପ୍ରୋସ୍କାର ଏବଂ ପ୍ରୋପେସିଆ, ଏକ ଔଷଧ ଯାହା ମୁଖ୍ୟତଃ ପୁରୁଷମାନଙ୍କ ମଧ୍ୟରେ ବର୍ଦ୍ଧିତ ପ୍ରୋଷ୍ଟେଟ୍ କିମ୍ବା କେଶହାନୀ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ |[୨] ଏହା ମହିଳାମାନଙ୍କର ଅତ୍ୟଧିକ କେଶ ବୃଦ୍ଧି ପାଇଁ ଏବଂ ଟ୍ରାନ୍ସଜେଣ୍ଡର ମହିଳାଙ୍କର ହରମୋନ ଥେରାପିର ଏକ ଅଂଶ ଭାବରେ ମଧ୍ୟ ବ୍ୟବହାର କରାଯାଇପାରିବ | [୩][୪] ଏହା ପାଟିରେ ଦିଆଯାଏ | [୫]

ଫିନଷ୍ଟେରାଇଡର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଅତି ବିରଳ,[୬] ତଥାପି କେତେକ ପୁରୁଷଙ୍କର ଯୌନ ଅସୁବିଧା, ଅବସାଦ ଏବଂ ସ୍ତନ ବୃଦ୍ଧି ଇପାରେ | [୭][୮] କେତେକ ପୁରୁଷଙ୍କଠାରେ ଔଷଧ ବନ୍ଦ କରିବା ପରେ ମଧ୍ୟ ଯୌନ ଅସୁବିଧା ହୋଇପାରେ | [୯][୧୦] ଏହା କେତେକ ପ୍ରକାରରପ୍ରୋଷ୍ଟେଟ କ୍ୟାନସରର ଆଶଙ୍କା ମଧ୍ୟ ବୃଦ୍ଧି କରିପାରେ |[୧୧] ଫିନାଷ୍ଟେରାଇଡ ହେଉଛି ୫α-ରିଡକ୍ଟେଜ ଇନହିବିଟର ଶ୍ରେଣୀର ଏକ ଔଷଧ ଏବଂ ସେଥିପାଇଁ ଏକ ଆଣ୍ଟିଆଣ୍ଡ୍ରୋଜେନ | [୧୨] ପ୍ରୋଷ୍ଟେଟ ଗ୍ରନ୍ଥି ଓ ସ୍କାଲ୍ପରେ ଏହା ଡିହାଇଡ୍ରୋଟେଷ୍ଟୋଷ୍ଟିରନ (DHT) ମାତ୍ରା ପ୍ରାୟ ୭୦% କମ୍ କରି ଏହା କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ | [୨]

ଫିନଷ୍ଟେରାଇଡ ୧୯୮୪ ମସିହାରେ ପେଟେଣ୍ଟ୍ ହୋଇଥିଲା ଏବଂ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ୧୯୯୨ ମସିହାରେ ।[୧୩] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | [୧୪] ଏହା ମହଙ୍ଗା ନୁହେଁ | [୧୫] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସ ଯୋଗାଣ ୨୦୧୯ ସୁଦ୍ଧା ପ୍ରତି ମାସରେ ୦.୯୦ ପା‌ଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ | [୧୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ, ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୨.୩୦ ଡଲାର ଅଟେ | [୧୭] ୨୦୧୭ ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୮୬ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ନଅ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା | [୧୮][୧୯]

ଆଧାର[ସମ୍ପାଦନା]

  1. ↑ ୧.୦ ୧.୧ ୧.୨ ୧.୩ ୧.୪ ୧.୫ ୧.୬ Lemke, Thomas L.; Williams, David A. (2008). Foye's Principles of Medicinal Chemistry (6th ed.). Lippincott Williams & Wilkins. pp. 1286–. ISBN 978-0-7817-6879-5. Archived from the original on 8 September 2017. Retrieved 1 August 2020.
  2. ↑ ୨.୦ ୨.୧ "Finasteride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 25 August 2018. Retrieved 5 March 2019.
  3. ↑ Blume-Peytavi, Ulrike; Whiting, David A.; Trüeb, Ralph M. (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. p. 369. ISBN 978-3-540-46911-7. Archived from the original on 11 January 2020. Retrieved 1 August 2020.
  4. ↑ Knezevich EL, Viereck LK, Drincic AT (January 2012). "Medical management of adult transsexual persons". Pharmacotherapy. 32 (1): 54–66. doi:10.1002/PHAR.1006. PMID 22392828.
  5. ↑ "Finasteride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 25 August 2018. Retrieved 5 March 2019.
  6. ↑ Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ (October 2010). "Finasteride for benign prostatic hyperplasia". The Cochrane Database of Systematic Reviews (10): CD006015. doi:10.1002/14651858.CD006015.pub3. PMID 20927745.
  7. ↑ Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS (2019-07-01). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". J Am Acad Dermatol. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792.
  8. ↑ Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508.
  9. ↑ Zakhem, GA; Goldberg, JE; Motosko, CC; Cohen, BE; Ho, RS (July 2019). "Sexual dysfunction in men taking systemic dermatologic medication: A systematic review". Journal of the American Academy of Dermatology. 81 (1): 163–172. doi:10.1016/j.jaad.2019.03.043. PMID 30905792. In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies CAPSULE SUMMARY d Prescription medications are a common cause of sexual dysfunction. Possible sexual adverse effects should be discussed with men using these medications. d We identified evidence for sexual adverse effects in patients taking 11 systemic dermatologic medications. Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
  10. ↑ Traish, AM (January 2020). "Post-finasteride syndrome: a surmountable challenge for clinicians". Fertility and Sterility. 113 (1): 21–50. doi:10.1016/j.fertnstert.2019.11.030. PMID 32033719.
  11. ↑ Varothai S, Bergfeld WF (July 2014). "Androgenetic alopecia: an evidence-based treatment update". American Journal of Clinical Dermatology. 15 (3): 217–30. doi:10.1007/s40257-014-0077-5. PMID 24848508.
  12. ↑ Ferri, Fred F. (2014). Ferri's Clinical Advisor 2015 E-Book: 5 Books in 1 (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 580. ISBN 9780323084307. Archived from the original on 6 June 2021. Retrieved 1 August 2020.
  13. ↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 483. ISBN 9783527607495. Archived from the original on 6 June 2021. Retrieved 1 August 2020.
  14. ↑ Sataloff, Robert T; Sclafani, Anthony P (30 November 2015). Sataloff's Comprehensive Textbook of Otolaryngology: Head & Neck Surgery: Facial Plastic and Reconstructive Surgery. JP Medical Ltd. pp. 400–. ISBN 978-93-5152-459-5. Archived from the original on 12 January 2020. Retrieved 1 August 2020.
  15. ↑ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (in ଇଂରାଜୀ) (2nd ed.). Elsevier. pp. 24–25. ISBN 978-0-7020-7442-4. Archived from the original on 22 May 2021. Retrieved 9 November 2021.
  16. ↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 769. ISBN 9780857113382.
  17. ↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  18. ↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  19. ↑ "Finasteride - Drug Usage Statistics". ClinCalc. Archived from the original on 6 February 2020. Retrieved 11 April 2020.
"https://or.wikipedia.org/w/index.php?title=ଫିନାଷ୍ଟେରାଇଡ&oldid=480364"ରୁ ଅଣାଯାଇଅଛି